Piñana, José LuisLópez-Corral, LuciaMartino, RodrigoMontoro, JuanVazquez, LourdesPérez, AriadnaMartin-Martin, GabrielFacal-Malvar, AnaFerrer, ElenaPascual, María-JesúsSanz-Linares, GabrielaGago, BeatrizSanchez-Salinas, AndrésVillalon, LuciaConesa-Garcia, VenancioOlave, Maria TLópez-Jimenez, JavierMarcos-Corrales, SaraGarcía-Blázquez, MartaGarcia-Gutiérrez, ValentínHernández-Rivas, José ÁngelSaus, AnaEspigado, IldefonsoAlonso, CarmenHernani, RafaelSolano, CarlosFerrer-Lores, BlancaGuerreiro, ManuelRuiz-García, MontserratMuñoz-Bellido, Juan LuisNavarro, DavidCedillo, AngelSureda, AnnaInfectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC)2023-05-032023-05-032021-11-02http://hdl.handle.net/10668/19952This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3-6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of the recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopeniaenAdolescentAdultAgedAntibodies, ViralCOVID-19COVID-19 VaccinesFemaleHematopoietic Stem Cell TransplantationHumansImmunocompromised HostMaleMiddle AgedProspective StudiesSARS-CoV-2SpainYoung Adultresearch article34695229open access10.1002/ajh.263851096-8652PMC8646900https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.26385https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646900/pdf